evidence table
Red Yeast Rice and Cholesterol Evidence Table
Structured evidence table for Red Yeast Rice and Cholesterol, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Red Yeast Rice and Cholesterol | Conclusion These results highlight the potential of monacolin K as a promising adjunct therapy for hypercholesterolemia management, especially for patients who have not achieved LDL-C targets with standard care or are intolerant to or unwilling to use statin therapy. | 1 | Jamialahmadi T (2026) | Impact of Monacolin K-Containing Supplements on Lipid Profile: A Meta-Analysis of Randomised Controlled Trials. |
| Red Yeast Rice and Cholesterol | Background Natural products have gained attention as alternative strategies for managing dyslipidemia, particularly in individuals who are resistant or unwilling to use conventional pharmacotherapies. | 1 | Jamialahmadi T (2026) | Impact of Monacolin K-Containing Supplements on Lipid Profile: A Meta-Analysis of Randomised Controlled Trials. |
| Red Yeast Rice and Cholesterol | Monacolin K, a compound derived from natural sources, has demonstrated potential benefits in improving lipid profile indices across various doses and supplementation durations. | 1 | Jamialahmadi T (2026) | Impact of Monacolin K-Containing Supplements on Lipid Profile: A Meta-Analysis of Randomised Controlled Trials. |
| Red Yeast Rice and Cholesterol | 1 2 3 4 5 6 7 8 9 10 The concept of metabolic syndrome was first introduced in 1988 as “Syndrome X” to describe the frequent clustering of insulin resistance with metabolic abnormalities that increase the risk of type 2 diabetes mellitus and cardiovascular disease [,]. | 3 | Starvaggi Josè (2026) | Selected Nutraceuticals in Metabolic Syndrome: Molecular Mechanisms and Clinical Implications |
| Red Yeast Rice and Cholesterol | This definition identifies metabolic syndrome based on the presence of at least three of the following components: increased waist circumference (population specific), hypertriglyceridemia and/or reduced HDL cholesterol, elevated blood pressure, and impaired fasting glucose [,]. | 3 | Starvaggi Josè (2026) | Selected Nutraceuticals in Metabolic Syndrome: Molecular Mechanisms and Clinical Implications |
| Red Yeast Rice and Cholesterol | 15 16 17 14 18 Accumulating evidence indicates that fat distribution rather than total adiposity is the principal determinant of metabolic risk. | 3 | Starvaggi Josè (2026) | Selected Nutraceuticals in Metabolic Syndrome: Molecular Mechanisms and Clinical Implications |
| Red Yeast Rice and Cholesterol | The term was later refined to “metabolic syndrome” to avoid confusion with cardiac Syndrome X and to better reflect the underlying metabolic dysregulation []. | 3 | Starvaggi Josè (2026) | Selected Nutraceuticals in Metabolic Syndrome: Molecular Mechanisms and Clinical Implications |
Source documents